The only trial that previously evaluated a similar patient population is SOLOIST-WHF (Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure), which enrolled patients with type 2 diabetes hospitalized with or recently discharged after an episode of decompensated HF, and showed favorable effects of sotagliflozin, a mixed SGLT1/2 inhibitor, on the 12-item KCCQ score at 4 months (mean 4.1-point improvement compared with placebo).12 Our findings from EMPULSE add to these data in several ways. The gene discussed is SLC5A1; the disease is heart failure.